EUVIMEDOpdag EUVIMED
Crossref

Ivermectin: Is It to Be a Potent Therapeutic Option for COVID-19?

Shweta Sinha, Alka Sehgal, Rakesh Sehgal

Clinical Infection and Immunity · 2020

DOI: 10.14740/cii106 ↗

At a glance

Journal article in Clinical Infection and Immunity, 2020. Written by Shweta Sinha and 2 co-authors. Cited 1 times so far (Crossref).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

To the EditorThe emergence and spread of coronavirus disease 2019 (COV-ID-2019) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a pandemic, has led to a new public health crisis.The whole world is now frightened and is in a constant battle to overcome this unprecedented situation through various conventional and non-conventional approaches.As the disease spreads, various pharmaceutical industries and research communities around the world are actively exploring drugs that would be potentially effective in combating COVID-19 infection to decrease the morbidity and mortality associated with this virus.However, till date there is no specific treatment available and all the management is empirical, and mostly consists of supportive therapy.There are some older drugs which are being considered and may be repurposed for this purpose.In this context, ivermectin (22,23-dihydroavermectin B), a well-known anti-helminthic which was introduced in mid-1980s, as the most broad-spectrum anti-parasite medication ever [1], is in focus for its potential activity against SARS-CoV-2.It evinced ideal in various ways, as from being broad-spectrum and highly efficacious to well-tolerated and safe with a wide therapeutic index, which could be administered easily (a single, annual oral dose).It is deployed in the treatment of various internal nematode infections, including onchocerciasis, filariasis, trichuriasis, strongyloidiasis, ascariasis, gnathostomiasis, and cutaneous larva migrans and also given as an oral treatment in case of infections with ectoparasitic, such as scabies (mite infestation) and pediculosis (lice infestation) [2].A recent study done by Caly et al, 2020 [3] demonstrated the antiviral activity of ivermectin against the SARS-CoV-2 clinical isolate under in vitro conditions.The result shows a

Cite

APA

Sinha, S., Sehgal, A., & Sehgal, R. (2020). Ivermectin: Is It to Be a Potent Therapeutic Option for COVID-19?. Clinical Infection and Immunity. https://doi.org/10.14740/cii106

Vancouver

Sinha S, Sehgal A, Sehgal R. Ivermectin: Is It to Be a Potent Therapeutic Option for COVID-19?. Clinical Infection and Immunity. 2020. doi:10.14740/cii106

BibTeX
@article{Sinha2020,
  author = {Sinha, Shweta and Sehgal, Alka and Sehgal, Rakesh},
  title = {Ivermectin: Is It to Be a Potent Therapeutic Option for COVID-19?},
  journal = {Clinical Infection and Immunity},
  year = {2020},
  doi = {10.14740/cii106}
}
Start for free →